1. Search Result
Search Result
Results for "

Cutaneous leishmaniasis

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Fluorescent Dyes

3

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1181A
    Pam2CSK4 TFA
    1 Publications Verification

    Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related Cardiovascular Disease Infection Inflammation/Immunology Cancer
    Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .
    Pam2CSK4 TFA
  • HY-P1181

    Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related Cardiovascular Disease Infection Inflammation/Immunology Cancer
    Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .
    Pam2CSK4
  • HY-U00128

    Parasite Infection Inflammation/Immunology
    PPA-904 is a specific phenothiazine photosensitizer in photodynamic research (PDT) research, especially topical application for cutaneous leishmaniasis in vivo .
    PPA-904
  • HY-162066

    Parasite Infection
    DNDI-6174 is an orally active Leishmania cytochrome b (Qi site of cytochrome bc1 complex/complex III) inhibitor. DNDI-6174 binds to the Qi site of Leishmania cytochrome b, inhibits cytochrome bc1 complex activity in the parasite's electron transport chain across promastigote and axenic amastigote stages. DNDI-6174 reduces parasite burden in rodent models, inhibits growth of various Leishmania species, drug-resistant clinical isolates, and Trypanosoma cruzi, with marginal activity against Trypanosoma brucei. DNDI-6174 can be used for the research of visceral leishmaniasis, cutaneous leishmaniasis .
    DNDI-6174
  • HY-129959

    AlClPc

    Environmental Pollutants Parasite MOFs Infection
    Aluminum phthalocyanine chloride is a photosensitizer that effectively inhibits the parasite Leishmania amazonensis (the causative agent of cutaneous leishmaniasis) by light-mediated cytolysis. Aluminum phthalocyanine chloride causes parasite morphology and cytolysis of isolated amasilians, while higher photosensitizer concentrations and light intensities are required to induce lysis of mammalian cells. Aluminum phthalocyanine chloride lyses parasites within infected J774 macrophages and can be used to further investigate the study of leishmaniasis .
    Aluminum phthalocyanine chloride
  • HY-N4267

    Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related Cardiovascular Disease Infection Inflammation/Immunology
    Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca 2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .
    Yangambin
  • HY-156132

    Parasite Infection
    DNDI-0690 is a potent orally active analogue of DNDI-VL-2098, exhibiting potent activity against cutaneous leishmaniasis (CL). DNDI-0690 shows potent in vitro activity against CL-causing Leishmania species (EC50 = 0.17 μM against visceral leishmaniasis (VL), and < 5 μM against CL-causing species). DNDI-0690 exerts effects in a mouse model of L. major CL. DNDI-0690 can be used for CL research .
    DNDI-0690
  • HY-146166

    Parasite Reactive Oxygen Species (ROS) Infection Inflammation/Immunology
    PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity .
    PT4
  • HY-173213

    Parasite Infection Inflammation/Immunology
    Antileishmanial agent-33 (4e), a hybrid compound of grandisin and machilin G, shows moderate activity on promastigotes (IC50 of 38.1 μM). Antileishmanial agent-33 (4e) shows potential as an antileishmanial agent for the research of cutaneous leishmaniasis (CL) .
    Antileishmanial agent-33
  • HY-W341759

    Parasite Infection
    1,4-Dihydrazinylphthalazine (Compound 2) is an antiparasitic agent targeting Leishmania spp. 1,4-Dihydrazinylphthalazine is promising for research of tropical diseases, particularly cutaneous leishmaniasis .
    1,4-Dihydrazinylphthalazine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: